EMPA-REG OUTCOME : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

EMPA-REG OUTCOME: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

• FDA approved for reduction of cardiac mortality in adults with T2DM and established CVD.

• Empagliflozin is a suggested add-on therapy to metformin for T2DM patients with established CVD (AACE 2019).

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.

>